MedTrace Logo

Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia

NCT00276263 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-06-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether preventative treatment with sarcosine can reduce symptoms and delay/avoid disease progression in individuals defined as being in a prodromal stage of schizophrenia.

Conditions

  • Schizophrenias
  • Psychoses
  • Psychotic Disorders
  • Schizophrenic Disorders

Interventions

DRUG

Sarcosine (N-methylglycine)

Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.

Sponsors & Collaborators

  • Herzog Hospital

    lead OTHER

Principal Investigators

  • Uriel Heresco-Levy, M.D. · Ezrath Nashim - Herzog Hospital / Hadassah Medical School

  • Bernard Lerer, M.D. · Department of Psychiatry, Hadassah Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Completion
2009-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276263 on ClinicalTrials.gov